Epixa-MR Tablet is a combination medication containing Etoricoxib 60 mg and Thiocolchicoside 4 mg, formulated for the management of musculoskeletal pain and inflammation. Etoricoxib, a selective COX-2 inhibitor, provides effective analgesic and anti-inflammatory effects by selectively blocking the cyclooxygenase-2 enzyme, thereby reducing the synthesis of prostaglandins involved in pain and inflammation. Thiocolchicoside, a muscle relaxant with anti-inflammatory properties, acts centrally by modulating glycine receptors and reducing muscle spasm, facilitating improved mobility and pain relief. Epixa-MR is indicated for the treatment of acute musculoskeletal conditions such as low back pain, osteoarthritis, rheumatoid arthritis, and soft tissue injuries where inflammation and muscle spasm coexist. The combination offers synergistic benefits by addressing both inflammatory pain and muscle stiffness, enhancing patient comfort and functional recovery. It is recommended to use Epixa-MR under medical supervision, with caution in patients with cardiovascular, hepatic, or renal impairments. Common adverse effects may include gastrointestinal discomfort, dizziness, and mild allergic reactions. Contraindications include hypersensitivity to either component, active peptic ulceration, and severe hepatic or renal dysfunction. Epixa-MR should be administered at the prescribed dose and duration to minimize risks and optimize therapeutic outcomes.